List of Excipients in Branded Drug DUOBRII

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	CARBOMER COPOLYMER TYPE B
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	CARBOMER HOMOPOLYMER TYPE A
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	DIETHYL SEBACATE
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	EDETATE DISODIUM
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	LIGHT MINERAL OIL
Bausch Health US LLC	DUOBRII	halobetasol propionate and tazarotene	0187-0653	METHYLPARABEN

DUOBRII Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

DUOBRII is a fixed-dose topical lotion combining halobetasol propionate 0.01% and tazarotene 0.045% for plaque psoriasis in adults. Its commercial differentiation depends on the vehicle as much as the active ingredients. The formulation uses a solvent and penetration-enhancement system built around diethylene glycol monoethyl ether and isopropyl myristate, supported by mineral oil, polysorbate 80, carbomer, sodium hydroxide, purified water, and butylated hydroxytoluene. The main commercial opportunities are generic and 505(b)(2) development, vehicle redesign, regional licensing, improved tolerability, and lifecycle extensions in inflammatory dermatoses. [1]

What is DUOBRII and how does its formulation work?

DUOBRII Lotion is manufactured by Ortho Dermatologics, a division of Bausch Health. The product was approved by the FDA on April 25, 2019, under NDA 210066. It is indicated for topical treatment of plaque psoriasis in adults and is applied once daily to affected areas. [1]

Product attribute	DUOBRII detail
Brand	DUOBRII Lotion
Active ingredients	Halobetasol propionate 0.01%; tazarotene 0.045%
Dosage form	Topical lotion
FDA application	NDA 210066
Approval date	April 25, 2019
Indication	Plaque psoriasis in adults
Administration	Once daily
Manufacturer	Ortho Dermatologics, Bausch Health
Product type	Fixed-dose topical combination
Biologic status	Not a biologic; biosimilar pathway does not apply

Halobetasol is a high-potency corticosteroid. Tazarotene is a topical retinoid. The formulation combines rapid anti-inflammatory activity with a retinoid intended to address abnormal keratinocyte differentiation and proliferation. The vehicle must deliver both compounds while controlling irritation, maintaining physical stability, and supporting patient adherence.

What excipients are used in DUOBRII?

The FDA prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation function	Commercial relevance
Diethylene glycol monoethyl ether	Solvent and penetration enhancer	Central to drug solubilization and skin delivery
Isopropyl myristate	Emollient and penetration enhancer	Supports spreadability and dermal partitioning
Light mineral oil	Occlusive emollient	Improves moisturization and barrier support
Polysorbate 80	Surfactant and solubilizer	Supports dispersion and formulation uniformity
Carbomer homopolymer Type B	Thickener and rheology modifier	Controls lotion viscosity and application behavior
Sodium hydroxide	pH adjustment and carbomer neutralization	Controls viscosity and product pH
Butylated hydroxytoluene	Antioxidant	Helps protect oxidation-sensitive components
Purified water	Continuous phase	Provides the aqueous base

[1]

Why is diethylene glycol monoethyl ether important?

Diethylene glycol monoethyl ether, commonly known as Transcutol or by related commercial names depending on grade and supplier, is strategically important because it can improve solubilization and dermal delivery. A formulation developer seeking to design around DUOBRII would need to establish whether a replacement solvent provides comparable:

• Solubility for halobetasol and tazarotene
• Skin permeation
• Product uniformity
• Viscosity
• Irritation profile
• Stability
• Preservative or microbial-control performance

A solvent substitution may create a meaningful formulation opportunity, but it also creates bioequivalence and clinical comparability risk.

What role does isopropyl myristate play?

Isopropyl myristate improves emolliency, spreadability, and skin penetration. It can also influence the partitioning of lipophilic actives into the stratum corneum. Replacing it with isopropyl palmitate, caprylic/capric triglyceride, oleyl alcohol, or another ester could produce a differentiated vehicle, but each substitute would change sensory characteristics and drug release.

The commercial value of an alternative ester would be highest if it reduced irritation or greasiness without reducing delivery of either active ingredient.

How does the carbomer and sodium hydroxide system affect the product?

Carbomer supplies viscosity and suspension control. Sodium hydroxide neutralizes the carbomer and adjusts pH, which affects viscosity, active stability, and skin tolerability. A developer changing the carbomer grade or neutralization system would need to evaluate:

• Viscosity across temperature ranges
• Phase separation
• Dose uniformity
• Container compatibility
• Pump or tube delivery
• Drug release and permeation
• Stability after opening

This excipient pair is a potential design-around area, but it is also a practical manufacturing risk. Small changes in neutralization can materially change the product’s application profile.

What formulations are protected by DUOBRII patents?

DUOBRII’s formulation protection is likely to be more commercially important than protection for either active ingredient. Halobetasol propionate and tazarotene are established compounds, so a generic developer would generally focus on the fixed combination, concentration, topical vehicle, manufacturing process, and method of use.

Relevant claim categories may include:

1. Fixed combinations of halobetasol propionate and tazarotene.
2. Specific concentration ranges for each active.
3. Lotion, cream, gel, foam, or emulsion vehicles.
4. Solvent and penetration-enhancer combinations.
5. Treatment regimens using the combination.
6. Stability or manufacturing processes.
7. Packaging systems that preserve product quality.

Patent scope must be assessed against the issued claims and current Orange Book listings rather than against the product label alone. The FDA Orange Book identifies patents submitted by the NDA holder and the associated expiration dates, while the USPTO Patent Center provides prosecution and post-grant records. [2,3]

How strong is the DUOBRII patent estate?

The estate is strongest where claims require the specific combination of:

• Halobetasol propionate and tazarotene
• Defined concentrations
• A topical lotion or emulsion
• Particular solvent, oil, surfactant, or rheology systems
• A defined treatment schedule

Composition claims covering a narrow vehicle can create a meaningful barrier if the formulation is difficult to reproduce without infringing. Broad claims covering the mere use of known actives are more vulnerable to validity and obviousness attacks, particularly where the prior art discloses corticosteroid-retinoid combinations or similar psoriasis regimens.

The commercial strength of the estate therefore depends on claim construction, written-description support, prosecution history, and whether a generic can use a materially different vehicle.

When does DUOBRII lose regulatory exclusivity?

DUOBRII received three-year new-drug exclusivity associated with the approval of a new combination or other qualifying change, rather than five-year new chemical entity exclusivity. The principal three-year period would have run from the April 25, 2019 approval date and generally would have ended in April 2022, subject to the exact FDA exclusivity designation and any pediatric extension. [1,4]

Exclusivity category	DUOBRII assessment
New chemical entity exclusivity	Not expected; both active ingredients were previously known
Three-year clinical-investigation exclusivity	Potentially applicable to the approved combination
Orphan-drug exclusivity	Not applicable to plaque psoriasis
Pediatric exclusivity	No extension should be assumed without an FDA-recognized award
Patent exclusivity	Controlled by issued patents and Orange Book listings
Biosimilar exclusivity	Not applicable

Regulatory exclusivity and patent exclusivity are separate. The end of three-year exclusivity does not eliminate an unexpired patent barrier.

What generic entry risks exist for DUOBRII?

A generic applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference lotion. The main technical risks include:

• Matching the active concentrations
• Demonstrating comparable drug release
• Demonstrating comparable skin permeation
• Controlling the ratio of dissolved and dispersed active
• Matching viscosity and spreadability
• Establishing container-closure compatibility
• Controlling degradation of tazarotene and halobetasol
• Addressing local irritation and sensitization

A generic manufacturer may choose either a close vehicle replication or a formulation that uses different excipients while meeting FDA equivalence requirements. The second strategy creates greater patent-design-around potential but raises regulatory risk.

What would a Paragraph IV challenge involve?

A Paragraph IV ANDA certification could assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. If the NDA holder receives proper notice and files suit within the statutory period, FDA approval can be subject to a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court developments. [4]

Likely challenge points would include:

• Obviousness of combining halobetasol and tazarotene
• Lack of written description for narrow excipient combinations
• Non-infringement based on a different solvent or emulsion structure
• Lack of enablement for broad vehicle claims
• Invalidity based on prior topical combination products
• Failure to demonstrate unexpected clinical or formulation benefits

The most credible generic strategy is likely to target narrow formulation claims first, then assess whether a non-infringing vehicle can satisfy FDA equivalence requirements.

What commercial opportunities exist for DUOBRII excipients?

Vehicle redesign for reduced irritation

Tazarotene can cause local irritation, dryness, erythema, and peeling. A competing vehicle could target a lower-irritation profile through:

• Alternative emollient systems
• Barrier-supportive lipids
• Controlled-release particles
• Lower solvent loading
• Improved moisturization
• More uniform dosing

A reduced-irritation formulation could support a 505(b)(2) strategy if it has a clinically meaningful advantage and cannot be readily supported through an ANDA route.

Premium generic or authorized-generic positioning

A generic developer could use the DUOBRII composition as a platform for:

• A lower-cost ANDA product
• An authorized generic arrangement
• A private-label dermatology product
• A differentiated lotion with improved sensory performance
• A hospital or managed-care formulation

The principal value driver is not excipient cost. Most excipients are inexpensive relative to development, analytical, clinical, regulatory, and litigation costs. The value lies in the ability to create a non-infringing product that still matches delivery and tolerability.

Regional licensing and supply opportunities

Excipient suppliers can pursue commercial agreements around:

• Pharmaceutical-grade diethylene glycol monoethyl ether
• Isopropyl myristate and substitute ester systems
• Carbomer grades
• Preservative-free or low-irritation vehicles
• Contract development and manufacturing
• Tube and pump packaging
• Stability-indicating analytical methods

A supplier with a validated excipient grade, reliable global supply, and dermatology formulation experience may become strategically important to a generic or 505(b)(2) developer.

New dosage forms

The DUOBRII actives could support investigation of alternative dosage forms, including:

• Creams
• Gels
• Foams
• Sprays
• Emulsions
• Film-forming systems
• Occlusive patch or localized delivery systems

Each dosage form would create a different regulatory and patent profile. A foam or spray could improve scalp or intertriginous application, while a cream or gel could target patients who dislike a lotion vehicle. The clinical benefit would need to justify a new development program.

How does DUOBRII compare with competing topical psoriasis products?

DUOBRII competes with topical corticosteroids, vitamin D analog combinations, retinoids, and nonsteroidal therapies.

Product category	Commercial advantage	Limitation relative to DUOBRII
High-potency corticosteroid monotherapy	Familiar, low-cost, rapid anti-inflammatory effect	Long-term steroid exposure and limited disease-modifying differentiation
Calcipotriene/betamethasone products	Established fixed-combination category	Different active mechanism and vehicle characteristics
Tazarotene monotherapy	Retinoid activity without corticosteroid exposure	Greater irritation and slower symptom relief for some patients
Nonsteroidal topical products	Avoid corticosteroid-related limitations	Often higher cost or different onset and efficacy profile
DUOBRII	Combines corticosteroid and retinoid in one lotion	Tazarotene irritation, steroid safety restrictions, and formulation complexity

DUOBRII’s main commercial proposition is convenience and combination therapy in a single product. Its main formulation vulnerability is the need to balance potency, irritation, cosmetic acceptability, and long-term use restrictions.

What is the FDA and Orange Book status of DUOBRII?

DUOBRII is an FDA-approved prescription topical product under NDA 210066. It is not a biologic, so biosimilar litigation, Purple Book listing, and biologic interchangeability do not apply. The relevant competitive pathway is ANDA approval under Hatch-Waxman, potentially combined with Paragraph IV patent challenges. [1,4]

The Orange Book should be used to confirm:

• Listed patents
• Patent-use codes
• Expiration dates
• Delisting activity
• Generic approval status
• Any exclusivity remaining on the reference product

Patent and litigation positions can change through settlements, terminal disclaimers, reexamination, post-grant review, or court decisions. An investment or licensing decision should rely on the current Orange Book and USPTO records rather than historical product-launch materials. [2,3]

What manufacturing and intellectual-property barriers matter most?

The leading barriers are formulation reproducibility and dermal equivalence. A technically simple excipient list can conceal complex processing requirements. Critical manufacturing variables may include:

• Order of excipient addition
• Carbomer hydration
• Sodium hydroxide neutralization rate
• Active dissolution sequence
• Shear conditions
• Temperature control
• Homogeneity during filling
• Light and oxygen protection
• Container interaction

The formulation may also be vulnerable to supply-chain concentration in specialty excipients. A developer should qualify multiple sources for the solvent, ester, carbomer, and antioxidant while preserving equivalent material specifications.

From an IP perspective, the most important question is whether a generic can change one or more excipients without losing bioequivalence. If yes, vehicle patents may have limited practical blocking power. If no, a narrow composition patent may create a stronger barrier than the active-ingredient claims suggest.

Key Takeaways

• DUOBRII is a fixed-dose halobetasol propionate and tazarotene lotion approved for adult plaque psoriasis.
• Its excipient strategy centers on diethylene glycol monoethyl ether, isopropyl myristate, light mineral oil, polysorbate 80, carbomer, sodium hydroxide, butylated hydroxytoluene, and water.
• The primary formulation opportunity is a lower-irritation or more cosmetically acceptable vehicle.
• Generic developers face dermal-equivalence, release, stability, and patent-design-around risks.
• DUOBRII is subject to Hatch-Waxman competition, not biosimilar competition.
• Three-year regulatory exclusivity would generally have ended in 2022, but unexpired patents may still delay generic entry.
• The strongest commercial opportunities are premium generics, 505(b)(2) reformulations, regional licensing, excipient supply, and contract development.
• Current Orange Book and USPTO records control the live patent and litigation assessment.

FAQs

Can a generic DUOBRII use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, safety, stability, and performance. A different vehicle may also reduce patent infringement risk.

Is DUOBRII eligible for biosimilar competition?

No. DUOBRII is a conventional small-molecule topical drug, not a biologic. Competition would generally proceed through an ANDA or, for a materially different formulation or indication, a 505(b)(2) application.

Which DUOBRII excipient is most important for drug delivery?

Diethylene glycol monoethyl ether is likely the most strategically important because it contributes to solubilization and dermal penetration. Isopropyl myristate also affects skin partitioning and product feel.

Could a foam formulation compete with DUOBRII lotion?

Yes, but a foam would require separate formulation, performance, regulatory, and patent analysis. Its strongest commercial rationale would be improved application to the scalp, hairy areas, or patients who prefer rapid drying.

Does changing the DUOBRII excipient system avoid all patent risk?

No. A reformulation may avoid a narrow vehicle claim but still infringe claims covering the active combination, concentrations, dosage regimen, treatment method, or other formulation characteristics.

References

1. U.S. Food and Drug Administration. (2019). DUOBRII (halobetasol propionate and tazarotene) lotion, prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. United States Patent and Trademark Office. (n.d.). Patent Center.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and Hatch-Waxman patent certifications.